Top 10 UK & EU Pharma Manufacturers CDMOs 2026
With 74% of Europe’s APIs still sourced from Asia, these are the UK and EU CDMOs positioned to capture reshoring demand in 2026.
Roughly 74% of Europe’s active pharmaceutical ingredients and precursor chemicals still originate from Asia — a concentration risk regulators and procurement teams have flagged repeatedly since pandemic-era disruptions. UK and EU CDMOs offering Western-headquartered, MHRA- or EMA-regulated manufacturing are positioned to capture reshoring demand. Here’s who’s actually building capacity to meet it.
1. Lonza
Lonza remains the technical benchmark across UK/EU biologics manufacturing, reporting an 11-12% sales growth outlook for 2026, driven largely by dominance in mammalian and bioconjugate production, alongside a completed ADC platform expansion at its Netherlands site.
2. Boehringer Ingelheim
Boehringer broke ground on a €285 million Chemical Innovation Plant in Ingelheim, Germany, with operations expected in 2026 — a meaningful signal of in-region manufacturing depth, even though not all output serves external CDMO clients.
3. Sterling Pharma Solutions
A UK-based CDMO supporting projects “from grams to tonnes” with a partnership-led service model, positioned as a scalable option for sponsors moving from clinical to commercial small-molecule production.
4. Cenexi
Now operating as a Europe platform under India-headquartered Gland Pharma following a 2023 majority stake transfer, Cenexi specializes in sterile products and stands to benefit as sponsors push more complex hospital injectables into outsourced channels.
5. NextPharma
A Europe-based CDMO with multiple facilities supporting projects from early development through commercial supply, offering sponsors geographic flexibility across the continent.
6. Eurofins CDMO
Centred on a Belgium footprint, Eurofins has built meaningful exposure to weight-management pipeline demand, though customer concentration on a few large programs remains a scheduling risk worth factoring into partner selection.
7. Sharp
Sharp committed over €20 million in January 2026 to expand injectable packaging, assembly, and cold-chain storage across Belgium and the Netherlands — directly relevant for sponsors prioritizing late-phase and commercial launch services.
8. Custom Pharma Services
A full-service CDMO specializing in guiding compounds from clinical development to commercial production, with particular strength in oral solid dose formulation.
9. SEKISUI Diagnostics
Completed a £15.7 million cGMP capacity expansion at its UK microbial fermentation site, enabling Grade C manufacturing for enzymes, proteins, antibody fragments, and gene therapy plasmids at up to 1,000-litre scale.
10. Rezon Bio (formerly Polpharma Biologics CDMO)
Launched in September 2025 following Polpharma Biologics’ demerger into two independent companies, Rezon Bio represents a newly independent biologics CDMO worth watching as it establishes its standalone commercial position.
What This Means for Procurement Teams
Regulatory pathway clarity is a genuine commercial advantage. UK sites benefit from an MHRA framework widely recognised internationally, giving sponsors relatively clear compliance pathways into both FDA and EMA markets simultaneously.
Ownership transitions signal risk and opportunity. Recent stake transfers and demergers (Cenexi, Rezon Bio) often precede portfolio pruning and operational modernization — worth monitoring closely if you’re mid-contract with an affected supplier.
Capacity investment is concentrated in sterile and injectable segments. Sharp’s cold-chain expansion and Cenexi’s hospital-injectable focus both point toward where near-term European capacity growth is actually happening.
FAQ
Why are UK and EU CDMOs gaining renewed attention?
Roughly 74% of Europe’s APIs currently come from Asia, and post-pandemic supply chain scrutiny has pushed sponsors to actively diversify away from single-geography exposure.
What regulatory advantage do UK CDMOs offer?
MHRA-regulated UK sites provide clear, internationally recognised compliance pathways into both FDA and EMA markets, simplifying multi-region commercial supply.
Which segment is seeing the most European CDMO investment?
Sterile and injectable manufacturing, including cold-chain and packaging capacity, is currently attracting the largest capital commitments across the region.
Sources
- GM Insights, Pharmaceutical CDMO Market Size Report
- ensun, Top CDMO Companies in United Kingdom 2026
- Mordor Intelligence, Europe Pharmaceutical Contract Manufacturing Companies
- papaverAI, British Pharma Contract Manufacturers 2026
- CDMOWorld, Top Pharmaceutical CDMO Companies 2026